@article{a720b0ad14e544cc9c4c66c42815697d,
title = "Is cigarette smoking a gateway to alcohol and illicit drug use disorders? A study of youths with and without attention deficit hyperactivity disorder",
abstract = "Background: The goal of this study was to assess whether cigarette smoking is a gateway drug for subsequent alcohol and illicit drug abuse and dependence in youth with Attention Deficit Hyperactivity Disorder (ADHD), and to test if this association is stronger in ADHD youth relative to controls. Methods: We used data from a case-control family study of female youth with and without ADHD. We studied 97 ADHD and 203 control youth of both sexes, aged at least 12 years. We assessed ADHD, smoking, and substance use status using structured diagnostic interviews. We tested the association between cigarette smoking and subsequent substance use outcomes using Cox proportional hazard regression models. Results: ADHD youth who smoked cigarettes (n = 15) were significantly more likely to subsequently use alcohol and illicit drugs as well as to develop abuse and dependence compared to ADHD youth who did not smoke (n = 76; p < .05). Conclusions: These results extend the gateway hypothesis to an ADHD sample and provide evidence that this effect may be particularly robust in ADHD youth. If replicated in larger, community-based samples, these findings have important public health consequences, and underscore the already pressing need to prevent smoking in ADHD children.",
keywords = "ADHD, Adolescents, Gateway, Smoking, Substance use, Substance use disorder",
author = "Joseph Biederman and Monuteaux, {Michael C.} and Eric Mick and Wilens, {Timothy E.} and Fontanella, {Jessie A.} and Poetzl, {Katrina M.} and Taralee Kirk and Joshua Masse and Faraone, {Stephen V.}",
note = "Funding Information: JB receives research support from the following sources: Shire Laboratories, Eli Lilly & Company, Pfizer Pharmaceutical, Cephalon Pharmaceutical, Janssen Pharmaceutical, Neurosearch Pharmaceuticals, Stanley Medical Institute, Lilly Foundation, Prechter Foundation, NIMH, National Institute of Child Health and Human Development (NICHD) and National Institute on Drug Abuse (NIDA). JB is a speaker for the following speaker{\textquoteright}s bureaus: Eli Lilly & Company, Pfizer Pharmaceutical, Novartis, Wyeth Ayerst, Shire Laboratories, McNeil Pharmaceutical, and Cephalon Pharmaceutical. JB is on the advisory board for the following pharmaceutical companies: Eli Lilly & Company, CellTech, Shire Laboratories, Novartis Pharmaceutical, Noven Pharmaceutical, McNeil Pharmaceuticals, Janssen, Johnson & Johnson, Pfizer, and Cephalon Pharmaceuticals. Funding Information: SVF receives research support from the following sources: McNeil Consumer & Specialty Pharmaceuticals, Shire, Eli Lilly & Company, NIMH, NICHD, and National Institute on Neurological Disorders and Stroke (NINDS). SVF is a speaker for the following speaker{\textquoteright}s bureaus: Eli Lilly & Company, McNeil and Shire. SVF has had an advisory or consulting relationship with the following pharmaceutical companies: McNeil, Noven, Shire, and Eli Lilly & Company. Funding Information: This work was supported, in part, by United States Public Health Service (National Institute of Mental Health [NIMH]) grant RO1 MH-41314-01A2 (JB) and RO1 DA14419 (TW). ",
year = "2006",
month = feb,
day = "1",
doi = "10.1016/j.biopsych.2005.07.009",
language = "English",
volume = "59",
pages = "258--264",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier Inc.",
number = "3",
}